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Abstract: Inflammation disturbs biochemical pathways involved in homeostasis of the endothelium. Research has estab-
lished clear links between inflammatory mediators, particularly C-reactive protein and tumour necrosis factor alpha,  
endothelial dysfunction, and atherosclerosis. Endothelial dysfunction and atherosclerosis may be subclinical at early 
stages, and thus the ability to detect them with non-invasive techniques is crucially important, particularly in populations 
at increased risk for cardiovascular disease, such as those with rheumatoid arthritis. This may allow the identification of 
interventions that may reverse these processes early on. One of the best non-pharmacological interventions that may 
achieve this is physical activity. This review explores the associations between inflammation, endothelial dysfunction,  
and atherosclerosis and discusses the role of exercise in blocking specific pathways in the inflammation, endothelial dys-
function - atherosclerosis network. 
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INTRODUCTION 
 The endothelium is now regarded as a dynamic organ 
lining the entire vascular system. It is responsible for many 
atheroprotective functions via its regulation of the immune 
response, fibrinolysis, coagulation, as well as multiple other 
functions related to vascular growth, vasoprotection, and 
vasoregulation. Disruption of normal endothelial function 
impedes its protective effects on vascular homeostasis, an 
early event characterizing the development of cardiovascular 
disease (CVD) [1-3]. Most importantly, endothelial dysfunc-
tion and the early stages of CVD may occur in the absence of 
any clinical symptoms. Hence, finding methods for assessing 
vascular dysfunction during the early stages of the disease is 
important, particularly in patient groups at high CVD risk 
[4].  
 Rheumatoid arthritis (RA) is the most common chronic 
inflammatory arthritis characterized by symptoms and signs 
of joint and systemic inflammation, joint destruction, body 
composition alterations, and physical disability. It also asso-
ciates with high CVD morbidity and mortality, which are  
not fully explained by the presence of traditional CVD risk 
factors [5-8]. In RA, increased local (synovial) and systemic 
expression of specific inflammatory mediators may have 
detrimental effects on the endothelium by enhancing bio-
chemical processes leading to its dysfunction and eventually  
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the development of atherosclerosis [2, 9]. Indeed, the  
inflammatory pathways involved in the pathogenesis of RA 
and atherosclerosis share many characteristics [10]. Inflam-
mation in RA is often evaluated by measuring the acute 
phase reactant C-reactive protein (CRP) and/or the erythro-
cyte sedimentation rate (ESR), which, in combination with 
other clinical markers (e.g. disease activity or X-ray scores), 
are used to assess the disease state and response to treatment 
[11]. The acute phase response is attributed to increased lev-
els of pro-inflammatory cytokines, such as tumour necrosis 
factor alpha (TNF-alpha) and interleukin-6 (IL-6) [10], 
which are individually or synergistically involved in many 
other disease processes, including joint destruction [12]  
altered body composition [13], and changes in vascular  
homeostasis [14, 15].  
INFLAMMATION AND ENDOTHELIAL DYSFUNC-
TION  
 The endothelium controls vascular function by releasing 
vasoactive factors such as nitric oxide (NO), prostacyclin 
(PGI2), and endothelin-1 (ET-1). Endothelial dysfunction 
occurs when the balance between these vasoactive factors is 
disturbed. The down-regulation of endothelial NO synthase 
(eNOS) plays an important role in this process [16]. Altered 
endothelial homeostasis due to the disturbed NO production is 
characterized by diminished endothelium-dependent dilation 
and increased expression of adhesion molecules, as well as 
changes in endothelial cell phenotype and increased endothe-
lial permeability [17]. Such changes in the structure and 
function of the endothelium are thought to be important as 
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initial stages in the pathogenesis of atherosclerosis and CVD 
[18].  
 Several studies have established a strong link between 
inflammation and endothelial dysfunction. In vitro, CRP 
modulates eNOS activity of human endothelial cells [19, 20] 
via uncoupling eNOS and subsequently increasing superox-
ide anions (oxidative stress) from NADPH oxidase [21]. As 
a result, phosphorylation of eNOS is decreased, and this  
subsequently reduces bioavailability of NO [22]. Apart from 
NO, CRP upregulates the expression of ET-1 which is a 
vasoconstrictor [23]. Studies also reveal a direct effect of 
TNF-alpha on dowregulating the expression of eNOS and 
diminishing endothelial NO [15]. TNF-alpha downregulates 
at the same time enzymatic activities of eNOS and 
argininosuccinate synthetase (regulator of citrulline/NO 
cycle) [24] and induces an increase in mRNA degradation of 
both eNOS and neuronal NO synthase promoting vasocon-
striction [25]. In addition, by activating NADPH oxidase, 
TNF-alpha stimulates the generation of reactive oxygen spe-
cies within the endothelial environment further impairing 
NO-mediated vasodilation [26]. Apart from inhibition of NO 
production, TNF-alpha may also be responsible for the re-
duction in the bioavailability of NO [27]. This is perhaps the 
main reason why TNF-alpha inhibition is directly linked to 
improved endothelial function in both RA [28] and non-RA 
populations [29].  
 Endothelial function and morphology are reported to be 
significantly worse in RA compared to healthy controls and 
this is attributed in large part to the high-grade inflammatory 
state of RA [30, 31]; in fact, acute inflammation (e.g. in re-
sponse to immunization) and low-grade chronic systemic 
inflammation (detected using high sensitivity CRP assays) in 
healthy individuals has been directly linked with arterial 
stiffness and vascular dysfunction [32, 33]. However, despite 
this biologically plausible link between inflammation and 
vascular dysfunction, there are still some controversies  
and inconsistent results in RA [34, 35], where some studies 
report a lack of association between systemic inflammatory 
load and endothelial function [36-38]. This may be attributed 
to different methodological approaches (e.g. using small, 
diverse patient populations cross-sectionally, or even smaller 
populations longitudinally but with short time courses), or 
lack of sufficient statistical power and no correction for mul-
tiple potential confounders (e.g. age and many CVD risk 
factors). The link between inflammation and vascular func-
tion appears to be more consistently demonstrated in homo-
geneous RA samples, such as young patients, patients with 
new onset RA and without established CVD [31, 39]. Vascu-
lar function may progressively deteriorate during the course 
of RA [40]. Hence, RA patients with long disease duration 
may already have significantly impaired endothelial function 
at the time of assessment, irrespective of disease “current” 
activity. Given the fluctuations in inflammation characteris-
tic of RA, it might be that longstanding, though intermittent, 
inflammatory insult to the endothelium is of more impor-
tance to vascular function in RA than the current level of 
inflammation [41]. Studies that took into account long-term 
inflammatory burden have been able to demonstrate associa-
tions between this and vascular function [36, 39].  
INFLAMMATION AND ATHEROSCLEROSIS 
 Endothelial cell dysfunction, evident as NO deficiency, 
appears to be amongst the earliest processes involved in 
atherosclerosis. Reduction of NO bioavailability disrupts the 
balance of the vasoactive factors, which allow ET-1 levels to 
increase and cause vasoconstriction [16]. Along with the 
biochemical mediators of endothelial function, mechanical 
forces and in particular, shear stress are also responsible for 
altering the phenotype of endothelial cells. Shear stress is the 
tangential stress that is applied to the artery wall and induces 
distension of the arteries; it is long-known that atheroscle-
rotic lesions originate mainly in areas of low shear stress, 
where flow is disturbed [42, 43]. In these areas, endothelial 
cells promote a pro-atherogenic phenotype [44], enhancing 
both the local selectivity of plaque formation, as well as ves-
sel wall remodeling, which, in turn, affects plaque vulner-
ability [45].  
 At the initial stages of atherosclerosis, leukocytes, par-
ticularly monocytes, progressively transmigrate through the 
endothelium with the help of monocyte chemoattractant pro-
tein 1 (MCP-1) and IL-8 [14]. Atherosclerosis progresses via 
the differentiation of monocytes into macrophages that retain 
low-density lipoproteins and become foam cells. Increased 
permeability of RA endothelial cells further enhances the 
entry of low-density lipoproteins and further promotes this 
cascade of events [46]. It has now been well-established that 
inflammation is involved in all phases of the atherothrom-
botic processes [2]. Whereas MCP-1 and IL-8 regulate 
monocyte transmigration, IL-8 can be upregulated in endo-
thelial cells by CRP via the NF-kB pathway [47]. CRP can 
also increase the expression of macrophage colony stimulat-
ing factor (M-CSF), responsible for the differentiation of 
monocytes into macrophages. Subsequently, macrophage 
proliferation increases, thereby enhancing the progression of 
atherosclerosis via the promotion of the formation of foam 
cells [48]. An alternative effect of CRP is to destabilize the 
atheromatous plaque at later stages of atherosclerosis, by 
upregulation of matrix metalloproteinases [49] which causes 
weakening of the plaque’s, fibrous cap. Apart from the 
above effects of CRP on these individual steps of atheroscle-
rosis, it also enhances fibrinolytic procedures within the en-
dothelial environment. CRP increases plasminogen activator 
inhibitor-1 mRNA through induction of the NF-kB signal-
ling pathway [50] and downregulates endothelial tissue 
plasminogen activator, a serine protease that is responsible 
for fibrinolysis. This biochemical process is orchestrated by 
TNF-alpha and IL-1b [51]. Other important atherogenic 
properties of CRP include CRP-induced oxidative stress via 
overproduction of reactive oxygen species [52]. Reactive 
oxygen species in the endothelium enhance degradation of 
eNOS via eNOS uncoupling and subsequent increase in su-
peroxide [53]. In general, superoxide reacts rapidly with NO, 
forming peroxynitrite which significantly impairs NO bioac-
tivity [54] and deteriorates endothelial function.  
 TNF-alpha has direct effects on endothelial permeability 
by altering the distribution of endothelial cadherin-catenin 
and inhibiting the re-structure of F-actin fibers [55]. This 
procedure may enable monocyte transmigration into the en-
dothelium and amplify the cascade of procedures that favor 
the formation of foam cells from macrophages [54]. Fur-
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thermore, the proliferation of macrophages and increased 
formation of foam cells enhances secretion of TNF-alpha in 
the endothelium, perpetuating this vicious atherogenic cycle 
[3]. TNF-alpha also upregulates membrane expression of 
vascular cell adhesion molecule-1 [56], which plays a well 
established role in atherosclerosis [57] and it precedes the 
development of thickened intima with foam cell lesions [58]. 
Apart from these in vitro observations, increased expression 
of serum TNF-alpha has been found in patients with athero-
sclerotic complications in population studies [59, 60]. In RA 
patients, TNF-alpha enhances prothrombotic states such as 
dyslipidemia [61], but, most importantly, pooled evidence 
reveals that anti-TNF-alpha treatment may be in part respon-
sible for reducing the risk for CVD events in RA [62]. Re-
cent studies also reveal that TNF-alpha is involved in the 
more advanced processes of atherosclerosis, specific to for-
mation of an advanced lesion via the inhibition of endothe-
lial progenitor cells [63]. In RA patients, endothelial pro-
genitor cell numbers are decreased compared to the healthy 
population [63], a phenomenon which reverses via blockade 
of TNF-alpha [64]. 
 Inflammation in RA associates with dramatic increases of 
IL-6, IL-1 and TNF-alpha levels, which can trigger the 
acute-phase response resulting in high CRP, and have direct 
effects on the endothelium that may enhance atherosclerotic 
processes. As such, uncontrolled inflammation is thought to 
be amongst the prime factors involved in the accelerated 
atherosclerosis in RA [1, 2].  
THE EFFECTS OF EXERCISE ON VASCULAR  
BIOLOGY 
 Increasing physical activity has been identified as one of 
the most important non-pharmacological interventions in 
both preventing and rehabilitating patients with non-
communicable chronic diseases such as CVD. This is  
because exercise reverses endothelial dysfunction and has 
important anti-atherogenenic and anti-inflammatory effects 
(Fig. 1). Most importantly, even compared to standardized 
interventional strategies, exercise may improve survival at 
lower treatment costs [65].  
Endothelial Function and Exercise 
 Exercise exerts significant effects on the endothelial  
system, both acutely and in the long term. These stimuli  
intervene and beneficially modify endothelial cell phenotype 
[17]. The acute effects of exercise are characterized by sig-
nificant increase in blood flow pertaining to the increased 
metabolic demands of the exercizing muscles and are closely 
related to the muscle fibre type recruitment (slow or fast 
twitch) as well as the duration and intensity of exercise [66]. 
The major mechanism responsible for exercise-induced  
hyperaemia is endothelial NO [67] and occurs due to the 
increased endothelial eNOS protein expression [68] as well 
as eNOS activation via Akt phosphorylation [69]. Exercise 
acutely increases local expression of endothelial progenitor 
cells (endothelial repair) as well as cultured/circulating angi-
ogenic cells which promote angiogenesis and endothelial 
growth [70]. Shear stress which is the result of exercise-
induced blood flow enhances intracellular mechanisms 
which increase eNOS transcription and upregulate anti-
oxidative mechanisms. Specifically, tyrosine kinase c-Src 
acts to increase eNOS and extracellular superoxide dismu-
tase expression, both of which relate to better endothelial 
function [71]. In addition, it has been well-established that 
shear stress increases the expression of PG I2, a vasodilator 
and inhibitor of platelet aggregation [72]. Furthermore, vas-
cular endothelial growth factor, which regulates capillary 
supply and exercise-induced angiogenesis, is significantly 
increased in response to exercise in both untrained and 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The effects of physical activity on endothelial function, atherosclerosis and inflammation. 
Exercise Anti-Atherogenic Effects 
Anti-Inflammatory Effects 
Reverses Endothelial Dysfunction 
 Increased Blood Flow 
 Increased eNOS 
 Improved anti-Oxidative Mechanisms 
 Increased Endothelial Progenitor Cells 
 Increased Prostaglandin 
 Increased Vascular Endothelial Growth 
Factor 
 Increased eNOS 
 Decreased Endothelin-1 
 Increased anti-Oxidative Capacity 
 Decreased adhesion molecules 
 Decreased selectins 
 Decreased monocyte chemoattractant 
protein 1 
 Decreased C-Reactive Protein 
 Reduced Adipose Tissue Size 
 Decreased expression of pro-inflammatory 
cytokines 
 Anti-inflammatory action of interleukin-6 
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trained individuals [73]. In the long term, the above  
mentioned physiological responses promote vascular  
remodelling, a necessary adaptation for improved oxygen 
exchange and blood flow delivery [74]. These long-term 
improvements are characterized by improved NO bioavail-
ability and/or endothelium-dependent vasodilation that may 
even reverse age-related vascular deterioration [75, 76].  
Improved endothelium-dependent vasodilation in response to 
long-term exercise is a consistent finding in both healthy 
[77] and disease populations [78].  
Anti-Atherogenic Effects of Exercise 
 Acutely, due to exercise-induced shear stress, eNOS 
mRNA expression increases while ET-1 decreases [79, 80], 
while concomitant changes involve down-regulation of  
vascular cell adhesion molecule 1 [81]. Oxidative stress  
accelerates atherogenesis via oxidation of retained low-
density lipoprotein, enhancing formation of foam cells [3]. 
An important long-term adaptation to exercise is the im-
provement in the anti-oxidative capacity of the human body, 
i.e. resistance to oxidative stress [82]. In particular, the en-
zymes catalase and superoxide dismutase which decompose 
reactive oxygen species are significantly increased as a result 
of habitual physical activity [83]. Increased eNOS in the 
endothelium increases anti-oxidant molecules such as super-
oxide dismutases 1 and 3 and angiotensin receptor type 2 and 
decreases oxidative molecules such as NADPH oxidase  
and angiotensin receptor type 1 [84]. Endothelial expression 
of adhesion molecules, selectins and MCP-1, all of which 
promote atherosclerosis, also decreases [85].  
Anti-Inflammatory Effects of Exercise  
 Physical activity and/or moderate intensity exercise have 
profound anti-inflammatory effects in the healthy population 
as well as patients with chronic diseases [86]. In population-
based studies, regular physical activity is consistently associ-
ated with a reduction in CRP levels [87, 88] which is also the 
case in patients with RA [89, 90]. The exact mechanisms 
whereby regular exercise reduces CRP have not yet been 
fully elucidated, but it seems that this association may exist 
via exercise-induced reduction in hypertension, triglycerides, 
and apolipoproteins, factors which are directly related to 
CRP concentration [91]. Most importantly, exercise reduces 
adipose tissue which is largely responsible for secretion of 
IL-6, a major trigger for hepatic production of CRP [92, 93]. 
However, these are physiological responses of moderate 
physical activity/exercise, whereas strenuous exercise  
may acutely promote an inflammatory response. CRP may 
increase immediately after prolonged strenuous exercise but 
returns to basal levels after approximately 48 hours, while 
this proportionate rise in CRP depends on the intensity of the 
exercise and the subsequent exercise-induced muscle dam-
age [94, 95].  
 Recent advances in muscle physiology reveal that muscle 
tissue is responsible for the production of myokines (muscle 
cytokines) suggesting that muscle is also an endocrine organ 
[96]. Muscle contractions regulate expression of specific 
cytokines such as IL-6, -8, -10, and -15, as well as IL-1  
receptor antagonist and TNF-alpha [96-98]. It is thought that, 
although IL-6 is predominantly a pro-inflammatory cytokine, 
it may also have under certain circumstances anti-inflamma- 
tory properties [99]. In that light, and based on the fact that 
IL-6 increases exponentially with acute exercise up to 100 
times compared to resting levels and returns to resting levels 
post-exercise [100], it has been suggested that IL-6 is the 
most important cytokine that induces the anti-inflammatory 
effects of exercise [96]. In contrast, pro-inflammatory cyto-
kines IL-1b and TNF-alpha do not generally increase in re-
sponse to moderate intensity exercise [101], whereas anti-
inflammatory cytokines such as IL-1ra and IL-10, signifi-
cantly increase [99, 102]. Interestingly, in response to regu-
lar exercise, IL-6 exerts its anti-inflammatory effects by  
primarily inhibiting the expression of TNF-alpha [99].  
Data have demonstrated that IL-6 inhibits lipopolysacharide-
induced TNF-alpha in human blood mononunclear cells 
[103], whereas TNF-alpha levels are overexpressed in IL-6 
deficient mice [104]. Recently, the transcriptional coactiva-
tor PGC1a has also attracted attention as it suppresses  
various inflammatory responses and regulates the effects of 
exercise [105] by coactivating transcription factors involved 
in biogenesis of mitochondria, oxidative phosphorylation 
and fatty acid oxidation [106, 107]. All these biological 
changes in cytokine expression in response to exercise, lead 
to beneficial long-term effects. Indeed, a consistent finding 
in the literature is that regular exercise relates to decreased 
systemic inflammation in both healthy and diseased popula-
tions [88, 89, 108, 109].  
EFFECTS OF EXERCISE ON CVD IN RA 
 The extensive damage of the joint structures in RA has 
initially led to the notion that RA patients should rest, as 
exercise may enhance joint damage [110]. However, during 
the last decade substantial evidence deriving from random-
ised trials reveals that exercise inhibits the progression of the 
disease and improves both wellbeing and functional ability 
of RA patients [90]. This is due to normal physiological 
processes which develop as a result of exercise training such 
as the improved muscle co-ordination and hypertrophy, re-
duced fat mass and better immune function. Patients that 
indeed have to refrain from specific exercises are those with 
extensive structural damage; in this occasion load of the 
damaged joints has to be avoided and can be replaced with 
alternative types of exercise. The beneficial effects of differ-
ent exercise training types on disease activity and severity 
have been confirmed several times by various studies [110, 
111] and hence, based on these evidence, exercise has now 
been incorporated in the management of RA [112]. It is, 
therefore imperative that RA patients embark on exercise 
training programmes. Although exercise is beneficial, in-
creasing physical activity in this population may prove diffi-
cult [113] perhaps due to the frequent advice from rheuma-
tology specialists to RA patients, that exercise may exacer-
bate disease symptoms [114]. However, data from published 
studies [110] of excellent quality as well as anecdotal  
evidence, reveal that RA patients should and can exercise at 
high intensities, and this is beneficial for various outcomes 
of this chronic disease. Moreover, studies have collectively 
shown that overall the adherence rates in exercise pro-
grammes can be high, presumably due to the fact that  
the significant improvements achieved via exercise promote 
self motivation [90].  
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 In a systematic review on exercise, CVD and RA, we 
found that, surprisingly, no studies have investigated the 
effects of exercise on CVD outcomes in this population [90]. 
However, given the ample evidence of the beneficial effects 
of physical activity/exercise on inhibiting disease progres-
sion and improving disease outcomes, we have proposed a 
model in which exercise should be incorporated in the man-
agement of the disease in order to prevent CVD, which is 
highly prevalent in this population. In this model, we suggest 
that effective treatment and control of inflammation should 
precede involvement in exercise in order to prohibit further 
damage and discomfort for the RA patient. Various drugs are 
available for patients with RA, including biological agents 
such as TNF-alpha, which target different biological path-
ways for inhibiting disease progression. Overall, medication 
strategies are effective in ameliorating disease activity (i.e. 
reduced expression of pro-inflammatory cytokines and 
CRP), a phenomenon that is also apparent as a response to 
exercise training. Nevertheless, given the lack of evidence 
regarding the effects of exercise on RA, potential changes in 
medication should always be based on robust clinical out-
comes and patient feedback.  
 Exercise involvement and/or increased physical activity 
are included in the management of many chronic diseases. In 
RA, where patients experience increased prevalence of 
CVD, exercise may be even more important due to its anti-
atherogenic and anti-inflammatory effects [17, 99]. The  
majority of studies on RA and exercise investigated the ef-
fects of physical activity/exercise regimens on improving 
RA-related disease outcomes. We have recently shown that 
physically inactive RA patients have worse CVD risk profile 
compared to physically active patients. In this cross-sectional 
study, we have investigated classical and novel risk factors, 
the prevalence of established CVD as well as the risk as-
sessment of developing CVDs in physically active as well as 
inactive RA patients. Regarding the novel CVD risk factors, 
our results revealed that parameters associated with vascular 
function (e.g. von Willebrand factor), fibrinolysis athero-
genesis (lipoproteins), pro-inflammatory cytokines, and CRP 
were markedly improved in patients who demonstrated  
increased levels of physical activity [89]. However, more 
research is required in order to investigate the potential  
associations of exercise on vascular function and CVD risk 
in this population as well as the mechanisms that underlie 
these associations.  
CONCLUSION 
 Evidence from basic research supports a clear association 
between inflammation, vascular dysfunction and atheroscle-
rosis. In RA, although evidence exists to support this asso-
ciation for atherosclerosis, the results are equivocal at least 
for endothelial dysfunction, potentially due to the differences 
in the methodological designs that do not take into account 
important factors that could influence endothelial function 
and atherosclerosis in RA. In addition, exercise has a protec-
tive effect via inhibiting the expression of inflammatory 
markers and their effects on both endothelial dysfunction and 
promotion of atherosclerosis. Future studies in RA should 
specifically investigate the effects of exercise regimes on 
endothelial function and atherosclerosis both in population 
studies and at a molecular level.  
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